Logo image of ECG

EVERUS CONSTRUCTION GROUP (ECG) Stock Fundamental Analysis

NYSE:ECG - New York Stock Exchange, Inc. - US3004261034 - Common Stock - Currency: USD

61.78  +0.04 (+0.06%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ECG. ECG was compared to 52 industry peers in the Construction & Engineering industry. ECG has only an average score on both its financial health and profitability. ECG is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ECG was profitable.
ECG Yearly Net Income VS EBIT VS OCF VS FCFECG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

The Return On Assets of ECG (11.20%) is better than 84.62% of its industry peers.
With an excellent Return On Equity value of 33.00%, ECG belongs to the best of the industry, outperforming 84.62% of the companies in the same industry.
With an excellent Return On Invested Capital value of 18.34%, ECG belongs to the best of the industry, outperforming 86.54% of the companies in the same industry.
ECG had an Average Return On Invested Capital over the past 3 years of 19.20%. This is above the industry average of 16.60%.
Industry RankSector Rank
ROA 11.2%
ROE 33%
ROIC 18.34%
ROA(3y)11.72%
ROA(5y)N/A
ROE(3y)32.38%
ROE(5y)N/A
ROIC(3y)19.2%
ROIC(5y)N/A
ECG Yearly ROA, ROE, ROICECG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 10 20 30

1.3 Margins

With a decent Profit Margin value of 4.98%, ECG is doing good in the industry, outperforming 71.15% of the companies in the same industry.
In the last couple of years the Profit Margin of ECG has declined.
With a decent Operating Margin value of 6.62%, ECG is doing good in the industry, outperforming 61.54% of the companies in the same industry.
In the last couple of years the Operating Margin of ECG has declined.
ECG has a Gross Margin of 11.71%. This is in the lower half of the industry: ECG underperforms 61.54% of its industry peers.
In the last couple of years the Gross Margin of ECG has remained more or less at the same level.
Industry RankSector Rank
OM 6.62%
PM (TTM) 4.98%
GM 11.71%
OM growth 3Y-2.11%
OM growth 5YN/A
PM growth 3Y-1.91%
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5YN/A
ECG Yearly Profit, Operating, Gross MarginsECG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2 4 6 8 10

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ECG is creating value.
ECG has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, ECG has a worse debt to assets ratio.
ECG Yearly Shares OutstandingECG Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
ECG Yearly Total Debt VS Total AssetsECG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ECG has an Altman-Z score of 5.56. This indicates that ECG is financially healthy and has little risk of bankruptcy at the moment.
ECG's Altman-Z score of 5.56 is fine compared to the rest of the industry. ECG outperforms 78.85% of its industry peers.
ECG has a Debt/Equity ratio of 0.60. This is a neutral value indicating ECG is somewhat dependend on debt financing.
ECG has a Debt to Equity ratio (0.60) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z 5.56
ROIC/WACC1.83
WACC10.04%
ECG Yearly LT Debt VS Equity VS FCFECG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

ECG has a Current Ratio of 1.78. This is a normal value and indicates that ECG is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.78, ECG belongs to the top of the industry, outperforming 86.54% of the companies in the same industry.
ECG has a Quick Ratio of 1.69. This is a normal value and indicates that ECG is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.69, ECG belongs to the top of the industry, outperforming 88.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.69
ECG Yearly Current Assets VS Current LiabilitesECG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

ECG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.30%.
ECG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.37% yearly.
ECG shows a decrease in Revenue. In the last year, the revenue decreased by -0.16%.
The Revenue has been growing by 11.57% on average over the past years. This is quite good.
EPS 1Y (TTM)4.3%
EPS 3Y9.37%
EPS 5YN/A
EPS Q2Q%29.68%
Revenue 1Y (TTM)-0.16%
Revenue growth 3Y11.57%
Revenue growth 5YN/A
Sales Q2Q%32.11%

3.2 Future

Based on estimates for the next years, ECG will show a small growth in Earnings Per Share. The EPS will grow by 1.26% on average per year.
The Revenue is expected to grow by 11.10% on average over the next years. This is quite good.
EPS Next Y-9.68%
EPS Next 2Y1.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.04%
Revenue Next 2Y11.1%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ECG Yearly Revenue VS EstimatesECG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 1B 2B 3B
ECG Yearly EPS VS EstimatesECG Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0.5 1 1.5 2 2.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 20.80, ECG is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of ECG indicates a rather cheap valuation: ECG is cheaper than 82.69% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.69, ECG is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 21.36, the valuation of ECG can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ECG indicates a somewhat cheap valuation: ECG is cheaper than 61.54% of the companies listed in the same industry.
ECG's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.29.
Industry RankSector Rank
PE 20.8
Fwd PE 21.36
ECG Price Earnings VS Forward Price EarningsECG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ECG is valued a bit cheaper than the industry average as 63.46% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.81
ECG Per share dataECG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.26%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ECG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVERUS CONSTRUCTION GROUP

NYSE:ECG (6/26/2025, 2:19:53 PM)

61.78

+0.04 (+0.06%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-05 2025-08-05
Inst Owners83.66%
Inst Owner Change5.67%
Ins Owners0.29%
Ins Owner Change24.43%
Market Cap3.15B
Analysts80
Price Target67.66 (9.52%)
Short Float %3.31%
Short Ratio2.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.93%
Min EPS beat(2)-3.53%
Max EPS beat(2)65.4%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)16.22%
Min Revenue beat(2)11.43%
Max Revenue beat(2)21.01%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.03%
PT rev (3m)7.57%
EPS NQ rev (1m)-4.61%
EPS NQ rev (3m)-2.77%
EPS NY rev (1m)1.53%
EPS NY rev (3m)1.67%
Revenue NQ rev (1m)-1.23%
Revenue NQ rev (3m)-2.14%
Revenue NY rev (1m)1.26%
Revenue NY rev (3m)1.59%
Valuation
Industry RankSector Rank
PE 20.8
Fwd PE 21.36
P/S 1.03
P/FCF N/A
P/OCF N/A
P/B 6.85
P/tB 9.94
EV/EBITDA 14.81
EPS(TTM)2.97
EY4.81%
EPS(NY)2.89
Fwd EY4.68%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS59.82
BVpS9.02
TBVpS6.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.2%
ROE 33%
ROCE 24.94%
ROIC 18.34%
ROICexc 20.19%
ROICexgc 25.07%
OM 6.62%
PM (TTM) 4.98%
GM 11.71%
FCFM N/A
ROA(3y)11.72%
ROA(5y)N/A
ROE(3y)32.38%
ROE(5y)N/A
ROIC(3y)19.2%
ROIC(5y)N/A
ROICexc(3y)19.99%
ROICexc(5y)N/A
ROICexgc(3y)25.54%
ROICexgc(5y)N/A
ROCE(3y)26.11%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.11%
OM growth 5YN/A
PM growth 3Y-1.91%
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover2.25
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA 1.22
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.69
Altman-Z 5.56
F-ScoreN/A
WACC10.04%
ROIC/WACC1.83
Cap/Depr(3y)170.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.42%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.3%
EPS 3Y9.37%
EPS 5YN/A
EPS Q2Q%29.68%
EPS Next Y-9.68%
EPS Next 2Y1.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.16%
Revenue growth 3Y11.57%
Revenue growth 5YN/A
Sales Q2Q%32.11%
Revenue Next Year12.04%
Revenue Next 2Y11.1%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.33%
EBIT growth 3Y9.22%
EBIT growth 5YN/A
EBIT Next Year18.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.21%
FCF growth 3Y25.55%
FCF growth 5YN/A
OCF growth 1Y-4.65%
OCF growth 3Y24.12%
OCF growth 5YN/A